| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 53,525 | 54,662 | ||
| Marketable securities | 40,863 | 41,362 | ||
| Accounts receivable, net of allowance for credit loss of 0 and 362 | 33,565 | 25,910 | ||
| Inventory | 9,476 | 8,591 | ||
| Prepaid expenses, current | 3,830 | 3,889 | ||
| Restricted cash, current | 2,091 | 2,091 | ||
| Other assets, current | 230 | 73 | ||
| Total current assets | 143,580 | 136,578 | ||
| Lease right-of-use assets, net | 6,147 | 2,828 | ||
| Property, plant and equipment, gross | 6,894 | - | ||
| Less accumulated depreciation | 6,589 | - | ||
| Property and equipment, net | 305 | 388 | ||
| Intangible assets, net | 43,827 | 46,262 | ||
| Restricted cash, long-term | 0 | 0 | ||
| Deferred tax assets | 7,075 | 7,075 | ||
| Prepaid expenses and other, long-term | 1,928 | 1,785 | ||
| Total assets | 202,862 | 194,916 | ||
| Accounts payable | 6,386 | 5,424 | ||
| Accrued expenses, current | 37,116 | 31,797 | ||
| Lease liabilities, current | 2,470 | 4,364 | ||
| Post-marketing commitment liability | 2,858 | 3,294 | ||
| Current portion of long-term debt | 33,716 | 33,997 | ||
| Other liabilities, current | 182 | 223 | ||
| Total current liabilities | 82,728 | 79,099 | ||
| Lease liabilities, long-term | 4,866 | 0 | ||
| Post-marketing commitment liability, long-term | 0 | 230 | ||
| Total long-term debt, net | 0 | 10,869 | ||
| Other liabilities, long-term | 0 | 0 | ||
| Total liabilities | 87,594 | 90,198 | ||
| Common stock - .0001 par value per share 100,000,000 shares authorized 50,384,274 shares issued and outstanding at september 30, 2025 and 49,105,834 issued and outstanding at december 31, 2024 | 5 | 5 | ||
| Additional paid-in capital | 1,412,457 | 1,410,784 | ||
| Accumulated other comprehensive income | 19 | -14 | ||
| Accumulated deficit | -1,297,213 | -1,306,057 | ||
| Total stockholders equity | 115,268 | 104,718 | ||
| Total liabilities and stockholders equity | 202,862 | 194,916 | ||
PUMA BIOTECHNOLOGY, INC. (PBYI)
PUMA BIOTECHNOLOGY, INC. (PBYI)